First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration Hospital Boca Raton, Florida, Jan. 28, 2025 (GLOBE NEWSWIRE) - ...
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial ...
A multicenter French study using full-length 16S rDNA sequencing found that men with prostate cancer harbor a more diverse ...
NEW YORK--(BUSINESS WIRE)--Massive Bio today announced it has entered a partnership with Veterans Prostate Cancer Awareness (VPCa), and Self-Care Catalysts to increase clinical trial and real-world ...
When implementing the ExoDx™ Prostate test in a real-world clinical setting, patients demonstrated improved compliance with the physician's recommendation to defer prostate biopsy when the test was ...
MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of ...
Prostate cancer affects about 500,000 members in the Veterans Health Administration, and Massive Bio is working with a nonprofit organization to boost enrollment in trials for the disease. (Penn ...
South Korean medical AI developer Deep Bio is deploying its prostate cancer diagnosis support software to five local hospitals as part of a recently signed trial purchase agreement. The AI product ...
Scientists at Duke University School of Medicine in Durham, North Carolina, have developed a small-molecule inhibitor of the cellular stress-protective transcription factor, heat shock factor 1 (HSF1) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results